AI Insight
Late-onset seizures in adults with Down syndrome are frequently linked to Alzheimer's disease progression, presenting as a condition called late-onset myoclonic epilepsy in Down syndrome (LOMEDS). These seizures, which manifest as myoclonic or tonic-clonic episodes, may both indicate underlying Alzheimer's pathology and potentially accelerate disease progression. The condition is likely under-recognized and undertreated in early stages, and the relationship between seizure onset timing and Alzheimer's symptom progression remains poorly understood.
Why it matters
Recognition of late-onset seizures as a potential indicator of Alzheimer's disease in Down syndrome patients could improve early detection and treatment strategies. Better understanding of this relationship may help clinicians more effectively manage cognitive decline in this vulnerable population and potentially slow disease progression through appropriate seizure management.
Understand the Science
Epilepsy is a common co-occurring condition in older adults with Down syndrome and frequently associated with the emergence of Alzheimer’s disease-related cognitive decline.1 Likely to be under-recognised and often untreated in the earlier stages, late-onset myoclonic epilepsy in Down syndrome (LOMEDS) presents as myoclonic or tonic–clonic seizures and can be both a manifestation of underlying Alzheimer’s disease pathology and an accelerator of disease progression.2 How seizure onset timing in adults with Down syndrome relates to Alzheimer’s disease symptoms and progression remains unclear, complicating interpretation of decline and clinical management.
Source: [Comment] Late-onset seizures as a sentinel of Alzheimer's disease progression in Down syndrome